BR112017003334A2 - variantes de desintegrina e usos farmacêuticos destas - Google Patents
variantes de desintegrina e usos farmacêuticos destasInfo
- Publication number
- BR112017003334A2 BR112017003334A2 BR112017003334A BR112017003334A BR112017003334A2 BR 112017003334 A2 BR112017003334 A2 BR 112017003334A2 BR 112017003334 A BR112017003334 A BR 112017003334A BR 112017003334 A BR112017003334 A BR 112017003334A BR 112017003334 A2 BR112017003334 A2 BR 112017003334A2
- Authority
- BR
- Brazil
- Prior art keywords
- disintegrin variants
- pharmaceutical uses
- disintegrin
- variants
- integrin
- Prior art date
Links
- 101800001224 Disintegrin Proteins 0.000 title abstract 3
- 108010044426 integrins Proteins 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010041014 Integrin alpha5 Proteins 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
Abstract
a presente invenção refere-se e descreve variantes de desintegrina que se ligam especificamente a uma ou mais das integrinas a5ß1 e av, tais como avß1, avß3, avß5, avß6 e avß8, mas com atividade de ligação à aiibß3 reduzida. a invenção descreve também usos das variantes de desintegrina para o tratamento ou a prevenção de uma doença associada com uma integrina av ou uma integrina a5ß1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462040503P | 2014-08-22 | 2014-08-22 | |
PCT/US2015/046322 WO2016029131A1 (en) | 2014-08-22 | 2015-08-21 | Disintegrin variants and pharmaceutical uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017003334A2 true BR112017003334A2 (pt) | 2017-11-28 |
BR112017003334A8 BR112017003334A8 (pt) | 2018-02-06 |
Family
ID=55351297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017003334A BR112017003334A8 (pt) | 2014-08-22 | 2015-08-21 | Variantes de desintegrina e usos farmacêuticos destas |
Country Status (13)
Country | Link |
---|---|
US (2) | US10508137B2 (pt) |
EP (1) | EP3182988A4 (pt) |
JP (1) | JP6886917B2 (pt) |
KR (1) | KR102102789B1 (pt) |
CN (1) | CN106714818B (pt) |
AU (1) | AU2015305299B2 (pt) |
BR (1) | BR112017003334A8 (pt) |
CA (1) | CA2958906C (pt) |
MX (1) | MX2017002323A (pt) |
RU (1) | RU2685869C1 (pt) |
SG (1) | SG11201700114WA (pt) |
TW (2) | TWI563001B (pt) |
WO (1) | WO2016029131A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI563001B (en) * | 2014-08-22 | 2016-12-21 | Univ Nat Cheng Kung | Disintegrin variants and pharmaceutical uses thereof |
KR20180012832A (ko) * | 2015-06-28 | 2018-02-06 | 올제네시스 바이오테라퓨틱스 아이엔씨. | 혈관신생 억제용 융합 단백질 |
IL247369B (en) * | 2016-08-18 | 2018-08-30 | B G Negev Tech And Applications Ltd | Polypeptides derived from CSF-m and their uses |
WO2018167295A1 (en) * | 2017-03-17 | 2018-09-20 | Technische Universität München | LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF |
US11202854B2 (en) * | 2017-08-09 | 2021-12-21 | National Taiwan University | Disintegrin variants and uses thereof |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380646A (en) * | 1992-10-19 | 1995-01-10 | Temple University Of The Commonwealth System Of Higher Education | Thrombus detection using radiolabelled disintegrins |
US7220724B2 (en) * | 1993-10-22 | 2007-05-22 | University Of Southern California | Contortrostatin CN and methods for its use in preventing metastasis and other conditions |
US7452551B1 (en) * | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
US20040010134A1 (en) * | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
AU2004223829A1 (en) * | 2003-03-24 | 2004-10-07 | Sequoia Pharmaceuticals, Inc. | Long acting biologically active conjugates |
US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
US8183201B2 (en) * | 2006-12-26 | 2012-05-22 | National Cheng Kung University | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin |
NZ597580A (en) * | 2009-07-20 | 2013-11-29 | Univ Nat Taiwan | Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof |
US9044436B2 (en) * | 2009-12-23 | 2015-06-02 | National Cheng Kung University | Compositions and methods for the treatment of angiogenesis-related eye diseases |
WO2011100362A1 (en) * | 2010-02-11 | 2011-08-18 | University Of Southern California | Modified adam disintegrin domain polypeptides and uses thereof |
US8946159B2 (en) * | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
WO2015048354A1 (en) * | 2013-09-25 | 2015-04-02 | Markland Francis S Jr | Compositions and methods for treating ovarian cancer including preventing the recurrence thereof |
TWI563001B (en) * | 2014-08-22 | 2016-12-21 | Univ Nat Cheng Kung | Disintegrin variants and pharmaceutical uses thereof |
KR20180012832A (ko) * | 2015-06-28 | 2018-02-06 | 올제네시스 바이오테라퓨틱스 아이엔씨. | 혈관신생 억제용 융합 단백질 |
-
2015
- 2015-08-21 TW TW104127347A patent/TWI563001B/zh active
- 2015-08-21 CN CN201580038532.7A patent/CN106714818B/zh active Active
- 2015-08-21 JP JP2017529973A patent/JP6886917B2/ja active Active
- 2015-08-21 EP EP15834216.2A patent/EP3182988A4/en active Pending
- 2015-08-21 CA CA2958906A patent/CA2958906C/en active Active
- 2015-08-21 US US15/505,357 patent/US10508137B2/en active Active
- 2015-08-21 KR KR1020177007653A patent/KR102102789B1/ko active IP Right Grant
- 2015-08-21 AU AU2015305299A patent/AU2015305299B2/en active Active
- 2015-08-21 WO PCT/US2015/046322 patent/WO2016029131A1/en active Application Filing
- 2015-08-21 SG SG11201700114WA patent/SG11201700114WA/en unknown
- 2015-08-21 BR BR112017003334A patent/BR112017003334A8/pt active Search and Examination
- 2015-08-21 MX MX2017002323A patent/MX2017002323A/es unknown
- 2015-08-21 RU RU2017105771A patent/RU2685869C1/ru active
- 2015-08-21 TW TW105137246A patent/TWI579299B/zh active
-
2019
- 2019-08-30 US US16/556,952 patent/US10870684B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2685869C1 (ru) | 2019-04-23 |
AU2015305299A1 (en) | 2017-02-09 |
EP3182988A1 (en) | 2017-06-28 |
MX2017002323A (es) | 2017-08-02 |
BR112017003334A8 (pt) | 2018-02-06 |
KR102102789B1 (ko) | 2020-04-24 |
JP2017525394A (ja) | 2017-09-07 |
CA2958906C (en) | 2021-05-04 |
RU2017105771A3 (pt) | 2018-09-24 |
AU2015305299B2 (en) | 2018-11-01 |
TW201708250A (zh) | 2017-03-01 |
JP6886917B2 (ja) | 2021-06-16 |
KR20170042366A (ko) | 2017-04-18 |
US10508137B2 (en) | 2019-12-17 |
CN106714818B (zh) | 2020-04-21 |
US20200010516A1 (en) | 2020-01-09 |
RU2017105771A (ru) | 2018-09-24 |
TWI563001B (en) | 2016-12-21 |
CA2958906A1 (en) | 2016-02-25 |
EP3182988A4 (en) | 2018-05-23 |
TWI579299B (zh) | 2017-04-21 |
CN106714818A (zh) | 2017-05-24 |
TW201609793A (zh) | 2016-03-16 |
US20170267731A1 (en) | 2017-09-21 |
US10870684B2 (en) | 2020-12-22 |
SG11201700114WA (en) | 2017-02-27 |
WO2016029131A1 (en) | 2016-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017003334A2 (pt) | variantes de desintegrina e usos farmacêuticos destas | |
CU20160185A7 (es) | Compuestos de heteroarilo para la inhibición de cinasa | |
BR112018004620A2 (pt) | moduladores da expressão de kras | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
BR112015019995A2 (pt) | Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer | |
BR112016012860A2 (pt) | Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
EA201790575A1 (ru) | Триазолопиразиноны в качестве ингибиторов pde1 | |
BR112016007467A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
CL2020001264A1 (es) | Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide. | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
BR112014028852A2 (pt) | agente para o tratamento profilático e/ou terapêutico de dor neuropática periférica causada por agente anticâncer. | |
BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
BR112018013256A2 (pt) | anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo | |
MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
BR112017010845A2 (pt) | uso de ligandos do receptor sigma em osteoartrite | |
CL2017001407A1 (es) | Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson | |
BR112015024877A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: NATIONAL CHENG KUNG UNIVERSITY (TW) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] |